CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Apr. 02, 2023	Dec. 31, 2022
Assets
Cash and cash equivalents		$ 2,166	$ 416
Short-term investments		17,806	22,316
Trade accounts receivable, less allowance for doubtful accounts: 2023—$465; 2022—$449		12,305	10,952
Inventories	[1]	9,541	8,981
Current tax assets		3,140	3,577
Other current assets		5,120	5,017
Total current assets		50,078	51,259
Equity-method investments		11,175	11,033
Long-term investments		3,568	4,036
Property, plant and equipment, less accumulated depreciation: 2023—$15,514; 2022—$15,174		17,052	16,274
Identifiable intangible assets	[2]	42,002	43,370
Goodwill		51,476	51,375
Noncurrent deferred tax assets and other noncurrent tax assets		7,302	6,693
Other noncurrent assets		12,965	13,163
Total assets		195,617	197,205
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2023—$3,567; 2022—$2,560		4,188	2,945
Trade accounts payable		6,123	6,809
Dividends payable		0	2,303
Income taxes payable		1,969	1,587
Accrued compensation and related items		2,277	3,407
Deferred revenues		1,750	2,520
Other current liabilities		20,255	22,568
Total current liabilities		36,562	42,138
Long-term debt		31,704	32,884
Pension and postretirement benefit obligations		2,179	2,250
Noncurrent deferred tax liabilities		1,067	1,023
Other taxes payable		9,860	9,812
Other noncurrent liabilities		13,009	13,180
Total liabilities		94,381	101,288
Commitments and Contingencies
Common stock		478	476
Additional paid-in capital		92,153	91,802
Treasury stock		(114,473)	(113,969)
Retained earnings		131,102	125,656
Accumulated other comprehensive loss		(8,289)	(8,304)
Total Pfizer Inc. shareholders’ equity		100,970	95,661
Equity attributable to noncontrolling interests		266	256
Total equity		101,236	95,916
Total liabilities and equity		$ 195,617	$ 197,205

[1] The increase from December 31, 2022 reflects higher inventory levels for Paxlovid and increases for certain products due to supply recovery and inventory build, partially offset by decreases due to market demand.

[2] The decrease is primarily due to amortization expense and impairments (see Note 4).